Український Державний Науково-Дослідний Інститут Реабілітації Інвалідів
Украинский Государственный Научно-Исследовательский Институт Реабилитации Инвалидов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Український Державний Науково-Дослідний Інститут Реабілітації Інвалідів, Украинский Государственный Научно-Исследовательский Институт Реабилитации ИнвалидовfiledCriticalУкраїнський Державний Науково-Дослідний Інститут Реабілітації Інвалідів
Priority to UA20040402943UpriorityCriticalpatent/UA4313U/en
Publication of UA4313UpublicationCriticalpatent/UA4313U/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The method for treating lupus erythematosus comprises the use of glucocorticoids, immunosuppressive agents, and non-steroid anti-inflammatory drugs. Furthermore, the subcutaneous injections of Eprex are prescribed thrice a week at a dose 150 Tg/kg, ascorbic acid is injected intramuscularly daily (2 ml of 5% solution), folic acid is administered at a daily dose of 5 mg, vitamin B1 is injected intramuscularly daily (1 ml of 2.5% solution), vitamin B6 is injected intramuscularly twice a day (1 ml of 5% solution), and vitamin B12 is injected intramuscularly every other day at a dose 100 g.
UA20040402943U2004-03-162004-03-16Method for treating lupus erythematosus
UA4313U
(en)